Maria Pascual PhD

María is currently Chief Regulatory Officer at Minoryx Therapeutics, a clinical-stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. María is a regarded strategic regulatory expert with 20 years’ experience in regulatory affairs with an extensive track record of leading global registration activities for innovative new products.

Prior to Minoryx, she was VP Regulatory Affairs and Quality at TiGenix bringing Alofisel from discovery to first allogeneic stem cell product to receive EMA marketing authorization resulting in an acquisition by Takeda. Board Member of EBE and member of EFPIA Regulatory Strategy Committee. Chaired regulatory working groups in various trade associations. Previous roles include VP Regulatory Affairs and Quality at Cellerix, a stem cell therapy company on immune-based diseases. Holds a bachelor’s degree in Pharmacy and a Ph.D. in Immunology and worked in R&D at the Mayo Clinic, USA and the LUMC in the Netherlands.